Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd PharmaphorumBoehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK.RespiratoryRead full story pharminent July 9, 2026 (Last updated: July 9, 2026) Pharmaphorum Boehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK. Respiratory Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Warning Letter Hits Sanofi’s Genzyme Ireland SiteNext: FDA freezes CRL trove as ‘radical transparency’ push hits speedbump Related Stories Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory EC approves AbbVie’s Tepkinly combination for follicular lymphoma pharminent July 7, 2026 Regulatory Novartis receives European Commission approval for Itvisma for spinal muscular atrophy pharminent July 2, 2026
